![European Commission investigation into Teva's potential abuse of dominance – misuse of patent procedures and disparagement | Allen & Overy LLP - JDSupra European Commission investigation into Teva's potential abuse of dominance – misuse of patent procedures and disparagement | Allen & Overy LLP - JDSupra](https://jdsupra-static.s3.amazonaws.com/profile-images/hr.15444_392.jpg)
European Commission investigation into Teva's potential abuse of dominance – misuse of patent procedures and disparagement | Allen & Overy LLP - JDSupra
Case C-198/19 P: Appeal brought on 28 February 2019 by Teva UK Ltd, Teva Pharmaceuticals Europe BV, Teva Pharmaceutical Industri
![Teva Pharmaceutical Industries Teva Pharmaceuticals Europe B.V. Pharmaceutical Industry Company NYSE:TEVA, PNG, 1248x682px, Teva Pharmaceutical Teva Pharmaceutical Industries Teva Pharmaceuticals Europe B.V. Pharmaceutical Industry Company NYSE:TEVA, PNG, 1248x682px, Teva Pharmaceutical](https://img.favpng.com/5/1/11/teva-pharmaceutical-industries-teva-pharmaceuticals-europe-b-v-pharmaceutical-industry-company-nyse-teva-png-favpng-q0rPFmTUfa78dQeDvHp7Jfn5K.jpg)
Teva Pharmaceutical Industries Teva Pharmaceuticals Europe B.V. Pharmaceutical Industry Company NYSE:TEVA, PNG, 1248x682px, Teva Pharmaceutical
![Teva Announces Promising Interim Results From Its Study PEARL, About the Impact of AJOVY® (fremanezumab) | Business Wire Teva Announces Promising Interim Results From Its Study PEARL, About the Impact of AJOVY® (fremanezumab) | Business Wire](https://mms.businesswire.com/media/20220624005272/en/739014/22/teva_RGB_JPEG.jpg)